6505--RSV Vaccine
ID: 36E79725R0043Type: Presolicitation
AwardedAug 25, 2025
$86.7M$86,670,525
AwardeeMODERNA US, INC. PRINCETON 08540 JIB
Award #:36E79725D0052
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNAC PHARMACEUTICALS (36E797)HINES, IL, 60141, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/e32d55a3bc9146d6bc0106de2a6b4225/view
Timeline
    Description

    The Department of Veterans Affairs (VA) is soliciting proposals for the procurement of Respiratory Syncytial Virus (RSV) vaccines through its Pharmaceutical Prime Vendor (PPV) program. Bidders are required to provide pricing for a base year and four option years, ensuring consistent availability and volume-based pricing, with the contract awarded to the most competitive offer. The RSV vaccine will serve as a mandatory supply for adults, with exceptions for clinical inappropriateness, and all offerors must comply with FDA guidelines and Drug Supply Chain Security Act (DSCSA) regulations. Interested parties should contact Contract Specialist Deborah S. Fassl at Deborah.Fassl@va.gov for further details and to ensure compliance with the submission requirements.

    Point(s) of Contact
    Deb Fassl and Nicholas McGregorContracting Officer
    Nicholas.McGregor@va.gov
    Deborah.Fassl@va.gov
    Files
    Title
    Posted
    36E79725R0043_1.docx
    The Department of Veterans Affairs (VA) is preparing to issue Request for Proposal (RFP) #36E79725R0043 to procure the Respiratory Syncytial Virus Vaccine (RSV Vaccine) for VA, Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Centers (FHCC). This procurement is unrestricted and aims to secure a reliable supply source for one year, with options for four additional yearly periods. The expected annual requirement is approximately 248,803 vials of the RSV Vaccine, which will be distributed through the VA’s and DoD’s Pharmaceutical Prime Vendor Programs. The RFP is set to be issued on or around June 2, 2025, with a response deadline of June 16, 2025. Offerors are required to provide detailed information on the vaccine products, including package sizes and unique NDC numbers. The awarded vaccine will serve as a mandatory source unless deemed clinically inappropriate for certain patient demographics. Interested parties should regularly check SAM.gov for updates, and any inquiries should be directed to the designated contracting officers via email.
    36E79725R0043.docx
    The document outlines a federal solicitation by the Department of Veterans Affairs (VA) for the procurement of Respiratory Syncytial Virus (RSV) vaccines through its Pharmaceutical Prime Vendor (PPV) program. The solicitation mandates that bidders provide prices for the base year and four additional option years, aiming for consistency in availability and volume-based pricing. The contract will be awarded to the entity that offers the most competitive pricing for specified quantities of vaccines. Offerors must comply with several stipulations, including maintaining unique National Drug Codes (NDCs) and adhering to FDA guidelines. The contract will establish a mandatory supply source unless specific clinical exceptions arise. It incorporates various federal acquisition clauses and emphasizes compliance with Drug Supply Chain Security Act (DSCSA) regulations regarding drug tracking. Offerors must submit comprehensive proposals, acknowledging all contract terms, and demonstrate manufacturing capability consistent with FDA standards. Regular reporting and fee payment obligations are also mandated. This document illustrates the VA's structured procurement process that aligns with federal regulations and emphasizes the importance of compliance and quality assurance in pharmaceutical supplies, reflecting the government's commitment to efficient health care delivery.
    36E79725R0043 0001.docx
    The document outlines an amendment to a solicitation related to a national contract for the respiratory syncytial virus (RSV) vaccine, managed by the Department of Veterans Affairs (VA). This amendment clarifies that the awarded RSV vaccine will be a mandatory supply for adults, with exceptions for clinical inappropriateness, such as patients falling outside the specified age range. The document emphasizes that all other terms and conditions of the original solicitation remain unchanged. The amendment is formally acknowledged by the contracting officer, Nicholas I. McGregor, highlighting adherence to established procurement procedures. This communication is essential to ensure that all participating offerors are informed of the changes to the contract, maintaining compliance and clarity in the government contracting process.
    Lifecycle
    Title
    Type
    6505--RSV Vaccine Effective 10/01/2025-09/30/30
    Award
    6505--RSV Vaccine
    Solicitation
    6505--RSV Vaccine
    Currently viewing
    Presolicitation
    Similar Opportunities
    6505--LEVOFLOXICIN 750MG / DEXTROSE 5% 150ML, IVPB (VA-26-00008212)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking small business vendors to supply LEVOFLOXICIN 750MG / DEXTROSE 5% 150ML, IVPB, as part of solicitation number 36C77026Q0005. This procurement involves delivering a total of 1,460 boxes of the pharmaceutical product to the VA CMOP facility in Hines, Illinois, with a base period and four option years, each requiring delivery by January 5th of the respective year. The goods are critical for patient care within the VA healthcare system, emphasizing the importance of timely and compliant delivery. Interested vendors must submit their proposals, including a signed SF 1449, pricing schedule, and other required documentation, by December 16, 2025, at 3 PM Central Time, and can direct inquiries to Contract Specialist Jennifer Coleman at Jennifer.Coleman4@va.gov.
    6505--Carbidopa Levodopa Immediate Release (IR) Tablets
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Carbidopa Levodopa Immediate Release (IR) Tablets, aimed at ensuring a reliable supply for various federal health care entities, including the VA, Department of Defense (DoD), and Bureau of Prisons (BOP). The procurement will involve awarding a single contract for an initial one-year period, with the possibility of four additional one-year option periods, to maintain an uninterrupted supply of these essential medications. The estimated annual requirements detail various dosages and package sizes, with total usage ranging from 2,008 to 118,764 bottles depending on the item. The solicitation is expected to be released around December 18, 2025, with a closing date of January 8, 2026; interested parties should direct inquiries to Ray Roldan at Raymond.Roldan@va.gov or call 708-786-4930.
    Pharmaceutical Repackaging Services for National CMOP (770)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting proposals for pharmaceutical repackaging services for the National Consolidated Mail Outpatient Pharmacy (CMOP) program. The contract, identified as 36C77026R0004, is a firm-fixed-price, indefinite-delivery agreement intended to support the repackaging of government-purchased oral solid pharmaceuticals into various bottle sizes for distribution to over 7 million veterans. The contract spans a five-year ordering period from February 1, 2026, to January 31, 2031, with a potential six-month extension, and has a minimum value of $20 million and a maximum value of $125 million. Interested contractors should contact Renee Kreutzer at renee.kreutzer@va.gov for further details and must submit their proposals by the specified deadlines, ensuring compliance with all relevant regulations and standards.
    6505--Biologics by McKesson Specialty Pharmacy (Lenalidomide) (VA-26-00016920)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking qualified suppliers to provide Lenalidomide, a pharmaceutical product, for the Oscar G. Johnson VA Medical Center located in Iron Mountain, MI. This procurement will be conducted through a Brand Name or Equal Request for Quotation (RFQ) under firm-fixed price terms, following FAR Part 13 Simplified Acquisition Procedures. Lenalidomide is crucial for treating certain conditions, making this procurement significant for patient care within the VA system. Interested offerors must submit an itemized quote along with sufficient technical documentation via email to arneil.genus@va.gov by 3 p.m. Central on December 1, 2025, as telephone inquiries will not be accepted.
    R499--Sterile Compounding Compliance QA Program
    Veterans Affairs, Department Of
    The Department of Veterans Affairs, through the Network Contracting Office 17, is seeking proposals for a Sterile Compounding Compliance Quality Assurance Program, specifically set aside for Service-Disabled Veteran-Owned Small Businesses (SDVOSB). This program encompasses a range of services, including monthly garbing competency assessments, media fill tests, hazardous drug manipulation competency evaluations, and cleaning and disinfection competency checks, with a contract period extending from January 1, 2026, to December 31, 2030. The importance of this procurement lies in ensuring compliance and safety in sterile compounding practices, which are critical for patient care in healthcare settings. Interested parties must submit their proposals by December 5, 2025, at 12 PM CST, and can direct inquiries to Contracting Specialist Matt Lee at matthew.lee5@va.gov or by phone at 210-393-9281.
    6515--Oscillation & Lung Expansion Therapy (OLE) Equipment
    Veterans Affairs, Department Of
    The Department of Veterans Affairs, specifically the Veterans Health Administration's Network Contracting Office 5, is seeking information from qualified firms regarding the procurement of Oscillation & Lung Expansion Therapy (OLE) Equipment, particularly the Volara System (PVL1CAP). The equipment must meet specific requirements, including the ability to deliver therapy within 10 minutes, incorporate essential components such as a compressor, humidifier, and flow generator, and be designed for mobility and ease of use. This procurement is critical for enhancing patient care in respiratory therapy, and interested parties must submit their responses by December 22, 2025, at 12:00 PM EST, via email to Contract Specialist James Ferro at james.ferro@va.gov, including proof of business status and relevant company information.
    6505--Nicotine Lozenges MINI (VA-26-00020754)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Nicotine Mini Lozenges, specifically under solicitation number 36E79726R0007. This contract aims to ensure an uninterrupted supply of nicotine lozenges for the VA, Department of Defense (DOD), Bureau of Prisons (BOP), and Indian Health Service (IHS), with a contract duration of one year and four optional one-year extensions. The estimated annual requirements include 166,791 bottles of 2mg lozenges and 138,276 bottles of 4mg lozenges, which will be distributed through the VA and DOD Pharmaceutical Prime Vendor Programs. Interested offerors should note that the solicitation will be electronically issued around December 18, 2025, with a tentative closing date of January 1, 2026, and can direct inquiries to Billy Fong at billy.fong@va.gov or by phone at 708-786-4992.
    SPS Services
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking proposals for SPS Services, as outlined in the attached documentation. The procurement aims to fulfill specific medical service requirements under the jurisdiction of the Veterans Affairs Network Contract Office 17. These services are critical for supporting the healthcare needs of veterans, ensuring they receive timely and effective medical care. Interested vendors can reach out to Dayna Cantu at dayna.cantu@va.gov or call 512-922-0142 for further details regarding the submission process and requirements.
    6505--Zonisamide Capsules
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking qualified suppliers for a Firm Fixed Price, Indefinite-Delivery Requirements contract for Zonisamide Capsules in 25mg, 50mg, and 100mg dosages. Offerors are required to provide pricing for a base year and four option years, submit a 0.5% Cost Recovery Fee, and comply with stringent packaging and barcoding standards, including adherence to the Drug Supply Chain Security Act (DSCSA) and National Drug Code (NDC) requirements. These pharmaceutical products are crucial for the healthcare services provided to veterans and military personnel through the VA and DoD Pharmaceutical Prime Vendor Programs. Interested parties should contact Contract Specialist Christopher Carthron at Christopher.Carthron@va.gov for further details, and ensure they meet all compliance and registration requirements, including current SAM registration.
    BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (BARDA), is seeking qualified contractors to support the development of vaccine medical countermeasures for pandemic influenza preparedness and response. The objective of this Sources Sought Notice (SSN) is to refine requirements and establish long-term partnerships with contractors capable of producing vaccines, antigens, and adjuvants necessary for pandemic preparedness and public health emergencies. This initiative is critical for enhancing the U.S. response to influenza viruses with pandemic potential and ensuring rapid regulatory decisions and manufacturing readiness. Interested parties must submit evidence of eligibility, capabilities statements, and requests to participate by email to Laura Saddison at Laura.Saddison@hhs.gov by 3:00 pm EST on December 19, 2025. This SSN/RFI is for information and planning purposes only and does not constitute a solicitation.